PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molmedLink to Publisher's site
 
Mol Med. 1997 January; 3(1): 5–20.
PMCID: PMC2230107

The CDKN2A (p16) gene and human cancer.

Abstract

CDKN2A, the gene encoding the cell-cycle inhibitor p16CDKN2A, was first identified in 1994. Since then, somatic mutations have been observed in many cancers and germline alterations have been found in kindreds with familial atypical multiple mole/melanoma (FAMMM), also known as atypical mole syndrome. In this review we tabulate the known mutations in this gene and discuss specific aspects, particularly with respect to germline mutations and cancer predisposition.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 1994 Jul 15;265(5170):415–417. [PubMed]
  • Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Hayakawa T. Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett. 1995 Nov 6;97(2):241–247. [PubMed]
  • Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br J Cancer. 1990 Jun;61(6):932–936. [PMC free article] [PubMed]
  • Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sørlie T, Hovig E, Smith-Sørensen B, Montesano R, Harris CC. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994 Sep;22(17):3551–3555. [PMC free article] [PubMed]
  • Li FP, Fraumeni JF, Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988 Sep 15;48(18):5358–5362. [PubMed]
  • Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10557–10561. [PubMed]
  • Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, 3rd, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. [PubMed]
  • Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992 Nov 13;258(5085):1148–1152. [PubMed]
  • Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH, Jr, Tucker MA. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet. 1994 Mar;54(3):489–496. [PubMed]
  • Nancarrow DJ, Mann GJ, Holland EA, Walker GJ, Beaton SC, Walters MK, Luxford C, Palmer JM, Donald JA, Weber JL, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet. 1993 Oct;53(4):936–942. [PubMed]
  • Gruis NA, Sandkuijl LA, Weber JL, van der Zee A, Borgstein AM, Bergman W, Frants RR. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res. 1993 Aug;3(4):271–277. [PubMed]
  • Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11045–11049. [PubMed]
  • Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 1994 Oct 15;54(20):5269–5272. [PubMed]
  • Spruck CH, 3rd, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA. p16 gene in uncultured tumours. Nature. 1994 Jul 21;370(6486):183–184. [PubMed]
  • Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995 Oct;11(2):210–212. [PubMed]
  • Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul;1(7):686–692. [PubMed]
  • Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995 Oct 15;55(20):4525–4530. [PubMed]
  • Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995 Oct 15;55(20):4531–4535. [PubMed]
  • Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996 Aug 15;56(16):3630–3633. [PubMed]
  • Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet. 1994 Sep;8(1):15–21. [PubMed]
  • Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet. 1995 Jul;10(3):351–353. [PubMed]
  • Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet. 1995 Oct;4(10):1845–1852. [PubMed]
  • Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH, Jr, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995 Oct 12;333(15):970–974. [PubMed]
  • Ciotti P, Strigini P, Bianchi-Scarrà G. Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group. N Engl J Med. 1996 Feb 15;334(7):469–472. [PubMed]
  • Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995 May;10(1):114–116. [PubMed]
  • Lynch HT, Fusaro RM, Pester J, Oosterhuis JA, Went LN, Rumke P, Neering H, Lynch JF. Tumour spectrum in the FAMMM syndrome. Br J Cancer. 1981 Oct;44(4):553–560. [PMC free article] [PubMed]
  • Greene MH, Tucker MA, Clark WH, Jr, Kraemer KH, Elder DE, Fraser MC. Hereditary melanoma and the dysplastic nevus syndrome: the risk of cancers other than melanoma. J Am Acad Dermatol. 1987 Apr;16(4):792–797. [PubMed]
  • Gutman M, Cnaan A, Inbar M, Shafir R, Chaitchik S, Rozin RR, Klausner JM. Are malignant melanoma patients at higher risk for a second cancer? Cancer. 1991 Aug 1;68(3):660–665. [PubMed]
  • Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 1995 Feb 15;273(7):564–570. [PubMed]
  • Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995 Dec;11(4):428–433. [PubMed]
  • Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med. 1995 Oct 12;333(15):975–977. [PubMed]
  • Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst. 1996 Oct 16;88(20):1489–1491. [PubMed]
  • Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. [PubMed]
  • Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer. 1996 Feb;15(2):77–88. [PubMed]
  • Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 1994 Dec 15;54(24):6353–6358. [PubMed]
  • Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M, Uchida K. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res. 1995 Jul 1;55(13):2756–2760. [PubMed]
  • Luca M, Xie S, Gutman M, Huang S, Bar-Eli M. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene. 1995 Oct 5;11(7):1399–1402. [PubMed]
  • Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene. 1995 Nov 2;11(9):1843–1851. [PubMed]
  • Huang L, Goodrow TL, Zhang SY, Klein-Szanto AJ, Chang H, Ruggeri BA. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res. 1996 Mar 1;56(5):1137–1141. [PubMed]
  • Zariwala M, Liu E, Xiong Y. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors. Oncogene. 1996 Jan 18;12(2):451–455. [PubMed]
  • Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology. 1996 Apr;110(4):1215–1224. [PubMed]
  • Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16,and p18 genes in osteosarcoma. Cancer Genet Cytogenet. 1996 Feb;86(2):136–142. [PubMed]
  • Brenner AJ, Aldaz CM. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res. 1995 Jul 1;55(13):2892–2895. [PubMed]
  • Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN, et al. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 1994 Oct 15;54(20):5262–5264. [PubMed]
  • Campbell IG, Foulkes WD, Beynon G, Davis M, Englefield P. LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer. 1995 Oct 9;63(2):222–225. [PubMed]
  • Hatta Y, Hirama T, Takeuchi S, Lee E, Pham E, Miller CW, Strohmeyer T, Wilczynski SP, Melmed S, Koeffler HP. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol. 1995 Nov;154(5):1954–1957. [PubMed]
  • Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990 Jan 5;247(4938):49–56. [PubMed]
  • Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton SR, Kern SE, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet. 1996 Jul;13(3):343–346. [PubMed]
  • Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Mad-related genes in the human. Nat Genet. 1996 Jul;13(3):347–349. [PubMed]
  • Reed JA, Loganzo F, Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995 Jul 1;55(13):2713–2718. [PubMed]
  • Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994 Sep;8(1):27–32. [PubMed]
  • Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Jr, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer. 1995 Nov;14(3):189–195. [PubMed]
  • Bartsch D, Shevlin DW, Callery MP, Norton JA, Wells SA, Jr, Goodfellow PJ. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst. 1996 May 15;88(10):680–682. [PubMed]
  • Eiriksdottir G, Sigurdsson A, Jonasson JG, Agnarsson BA, Sigurdsson H, Gudmundsson J, Bergthorsson JT, Barkardottir RB, Egilsson V, Ingvarsson S. Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int J Cancer. 1995 Dec 20;64(6):378–382. [PubMed]
  • Holland EA, Beaton SC, Becker TM, Grulet OM, Peters BA, Rizos H, Kefford RF, Mann GJ. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene. 1995 Dec 7;11(11):2289–2294. [PubMed]
  • Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994 Sep;8(1):23–26. [PubMed]
  • Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, Hogg D. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene. 1995 Jul 20;11(2):405–412. [PubMed]
  • Borg A, Johannsson U, Johannsson O, Häkansson S, Westerdahl J, Mäsbäck A, Olsson H, Ingvar C. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res. 1996 Jun 1;56(11):2497–2500. [PubMed]
  • Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet. 1994 Oct;3(10):1841–1845. [PubMed]
  • Musgrove EA, Lilischkis R, Cornish AL, Lee CS, Setlur V, Seshadri R, Sutherland RL. Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer. 1995 Nov 15;63(4):584–591. [PubMed]
  • Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood. 1995 Aug 15;86(4):1269–1275. [PubMed]
  • Calabrò V, Strazzullo M, La Mantia G, Fedele M, Paulin C, Fusco A, Lania L. Status and expression of the p16INK4 gene in human thyroid tumors and thyroid-tumor cell lines. Int J Cancer. 1996 Jul 3;67(1):29–34. [PubMed]
  • Nakamaki T, Kawamata N, Schwaller J, Tobler A, Fey M, Pakkala S, Lee YY, Kim BK, Fukuchi K, Tsuruoka N, et al. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br J Haematol. 1995 Sep;91(1):139–149. [PubMed]
  • de Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK, Koeffler HP. Alterations of CDKN2 (p16) in non-small cell lung cancer. Genes Chromosomes Cancer. 1995 Nov;14(3):164–170. [PubMed]
  • Okajima E, Fukuda T, Okita S, Tsutsumi M, Hirao Y, Okajima E, Konishi Y. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. Cancer Lett. 1996 Jun 5;103(2):227–231. [PubMed]
  • Platz A, Ringborg U, Lagerlöf B, Lundqvist E, Sevigny P, Inganäs M. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer. 1996 Feb;73(3):344–348. [PMC free article] [PubMed]
  • Rasool O, Heyman M, Brandter LB, Liu Y, Grandér D, Söderhäll S, Einhorn S. p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood. 1995 Jun 15;85(12):3431–3436. [PubMed]
  • Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. Blood. 1995 Oct 1;86(7):2724–2731. [PubMed]
  • Esteve A, Martel-Planche G, Sylla BS, Hollstein M, Hainaut P, Montesano R. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int J Cancer. 1996 May 3;66(3):301–304. [PubMed]
  • Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 1996 Jan 1;56(1):150–153. [PubMed]
  • Shimizu T, Sekiya T. Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers. Int J Cancer. 1995 Nov 27;63(5):616–620. [PubMed]
  • Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer. 1996 Apr;73(8):909–916. [PMC free article] [PubMed]
  • Ohta M, Berd D, Shimizu M, Nagai H, Cotticelli M-G, Mastrangelo M, Shields JA, Shields CL, Croce CM, Huebner K. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer. 1996 Mar 15;65(6):762–767. [PubMed]
  • Rusin MR, Okamoto A, Chorazy M, Czyzewski K, Harasim J, Spillare EA, Hagiwara K, Hussain SP, Xiong Y, Demetrick DJ, et al. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int J Cancer. 1996 Mar 15;65(6):734–739. [PubMed]
  • Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J. Mutations of the p16 gene in gliomas. Oncogene. 1996 Jan 4;12(1):63–67. [PubMed]
  • Berns EM, Klijn JG, Smid M, van Staveren IL, Gruis NA, Foekens JA. Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer. 1995 Oct;72(4):964–967. [PMC free article] [PubMed]
  • Nakao M, Yokota S, Kaneko H, Seriu T, Koizumi S, Takaue Y, Fujimoto T, Misawa S. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. Leukemia. 1996 Feb;10(2):249–254. [PubMed]
  • Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA, Jr, Goodfellow PJ. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol Carcinog. 1996 Jan;15(1):5–10. [PubMed]
  • Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood. 1996 Mar 15;87(6):2180–2186. [PubMed]
  • Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck CH, 3rd, Busch C, Shamaa M, El-Baz M, Nichols PW, Gonzalgo ML, Elbaz M [corrected to El-Baz M], et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst. 1995 Sep 20;87(18):1383–1393. [PubMed]
  • Sonoda Y, Yoshimoto T, Sekiya T. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene. 1995 Nov 16;11(10):2145–2149. [PubMed]
  • Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T, Terada M. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res. 1995 Aug 1;55(15):3421–3423. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ